A Phase 1 interventional study of RSVpreF 120 µg and RSVpreF 60 µg in RESPIRATORY SYNCYTIAL VIRUS (RSV), sponsored by Pfizer. Completed at 17 sites in United States. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Pfizer · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.
Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1, and was the 16th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
By country, each count listing its studies:
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 309 across the 18 interventional studies, 421 across the 5 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Respiratory Tract Infections by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Respiratory Tract Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to \<18 years of age.
This study will identify the dose level to be used in Phase 2/3 trials in this age cohort. All participants will receive one injection of RSVpreF. This study has four study visits, two in-clinic and two telehealth visits. Blood samples will be collected for testing. This study is about 6 months long for each participant and will be conducted in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants 2 to \<18 years of age should either be healthy or be considered by the investigator to be at high risk of RSV disease based on the presence of 1 of the following chronic medical conditions:
Exclusion Criteria:
Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic ), or radiotherapy, within 60 days before study intervention administration, or planned receipt throughout the study.
Note: Systemic corticosteroids are defined as those administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standard dose (120 µg)
Biological: RSVpreF 120 µg
standard dose (120 µg)
Biological: RSVpreF 120 µg
standard dose (120 µg)
Biological: RSVpreF 120 µg
low dose (60 µg)
Biological: RSVpreF 60 µg
low dose (60 µg)
Biological: RSVpreF 60 µg
low dose (60 µg)
Biological: RSVpreF 60 µg
RSVpreF standard dose level
RSVpreF low dose level
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after vaccination. Local reactions included pain at injection site, redness, and swelling. For participants greater than or equal to (\>=) 2 years to \<12 years of age, redness and swelling were graded as mild: 0.5 to 2.0 centimeter (cm), moderate: \>2.0 to 7.0 cm, and severe: \> 7 cm; for participants \>=12 years of age, mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, and severe: \>10 cm. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Day 1 through Day 7 after Vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, vomiting, diarrhea, muscle pain and joint pain and were recorded by participants using e-diary. Fever: oral temperature \>= 38.0 degree Celsius (deg C) and categorized as \>=38.0 to 38.4 deg C (mild), \>38.4 to 38.9 deg C (moderate), and \>38.9 to 40.0 deg C (severe). Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), and severe (prevented daily routine activity). Vomiting was graded mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, and severe: required intravenous hydration. Diarrhea was graded mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h.
Time frame: Day 1 through Day 7 after Vaccination
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
AE was defined as any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. AEs included serious and all non-serious AE. SAEs were defined as AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was congenital anomaly or birth defect; was suspected transmission via Pfizer product of infectious agent, pathogenic or nonpathogenic or was considered to be an important medical event. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were included.
Time frame: Within 1 month post Vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as an AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability or incapacity; was a congenital anomaly or birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic or that was considered to be an important medical event.
Time frame: Within 6 months post Vaccination
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study
An NDCMC was defined as a disease or medical condition, which was not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Within 6 months post Vaccination
Geometric Mean Titer of the Neutralizing Titers for RSV A and RSV B Before Vaccination and 1 Month After Vaccination
Geometric mean titer (GMT) of neutralizing titers (NTs) of respiratory syncytial virus subgroup A and respiratory syncytial virus subgroup B (RSV A and RSV B) before vaccination and 1 month after vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).
Time frame: Before vaccination and 1 month after vaccination
Geometric Mean Fold Rise (GMFR) of the NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
GMFR of neutralizing titers of RSV A and RSV B from before vaccination to 1 month after vaccination were reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).
Time frame: From before vaccination to 1 month after vaccination
Median Frequencies of RSV F Antigen-Specific Cluster of Differentiation 4 (CD4+) Thymus-Derived Lymphocytes (T) Cells Expressing Interferon (IFN) Gamma and Interleukin-4 (IL-4) Before Vaccination and 1 Month After Vaccination
Median frequencies of RSV F antigen-specific CD4+ T cells expressing IFN gamma and IL-4 before vaccination and 1 month after vaccination were reported in this outcome measure. RSV F enzyme-linked immune absorbent spot assay (ELISpot) limit of detection (LOD) values were IFN gamma = 20 spot forming cell (SFC) per million peripheral blood mononuclear cell (PBMCs) and IL-4 = 4 SFC/million PBMCs. Assay results below LOD=0.5\*LOD for analysis. Frequencies were defined as the count of the RSV F antigen-specific CD4+ T cells and median frequencies were defined as the median of the counts.
Time frame: Before vaccination and 1 Month after vaccination
A total of 128 participants were enrolled, however 1 participant was assigned to a vaccine group but did not receive vaccination. Consequently, a total of 127 participants were vaccinated.
| Milestone | RSVpreF 120 Micrograms (mcg): 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years |
|---|---|---|---|---|---|---|
| Started | 25 | 23 | 24 | 17 | 18 | 20 |
| Completed | 25 | 23 | 24 | 17 | 18 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | RSVpreF 120 Micrograms (mcg): 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years |
|---|---|---|---|---|---|---|
| Started | 25 | 23 | 24 | 17 | 18 | 20 |
| Completed | 24 | 21 | 23 | 17 | 17 | 19 |
| Not completed | 1 | 2 | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 0 | 1 | 1 |
Local reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after vaccination. Local reactions included pain at injection site, redness, and swelling. For participants greater than or equal to (\>=) 2 years to \<12 years of age, redness and swelling were graded as mild: 0.5 to 2.0 centimeter (cm), moderate: \>2.0 to 7.0 cm, and severe: \> 7 cm; for participants \>=12 years of age, mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, and severe: \>10 cm. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| Pain at injection site: Mild | 36.0 (18.0 to 57.5) | 39.1 (19.7 to 61.5) | 8.3 (1.0 to 27.0) | 35.3 (14.2 to 61.7) | 33.3 (13.3 to 59.0) | 15.0 (3.2 to 37.9) |
| Pain at injection site: Moderate | 8.0 (1.0 to 26.0) | 8.7 (1.1 to 28.0) | 0 (0.0 to 14.2) | 5.9 (0.1 to 28.7) | 22.2 (6.4 to 47.6) | 0 (0.0 to 16.8) |
| Pain at injection site: Severe | 4.0 (0.1 to 20.4) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Redness: Mild | 12.0 (2.5 to 31.2) | 4.3 (0.1 to 21.9) | 12.5 (2.7 to 32.4) | 0 (0.0 to 19.5) | 11.1 (1.4 to 34.7) | 5.0 (0.1 to 24.9) |
| Redness: Moderate | 12.0 (2.5 to 31.2) | 4.3 (0.1 to 21.9) | 0 (0.0 to 14.2) | 5.9 (0.1 to 28.7) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Redness: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Swelling: Mild | 4.0 (0.1 to 20.4) | 0 (0.0 to 14.8) | 4.2 (0.1 to 21.1) | 0 (0.0 to 19.5) | 11.1 (1.4 to 34.7) | 0 (0.0 to 16.8) |
| Swelling: Moderate | 8.0 (1.0 to 26.0) | 8.7 (1.1 to 28.0) | 0 (0.0 to 14.2) | 5.9 (0.1 to 28.7) | 11.1 (1.4 to 34.7) | 5.0 (0.1 to 24.9) |
| Swelling: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
Systemic events included fever, fatigue, headache, vomiting, diarrhea, muscle pain and joint pain and were recorded by participants using e-diary. Fever: oral temperature \>= 38.0 degree Celsius (deg C) and categorized as \>=38.0 to 38.4 deg C (mild), \>38.4 to 38.9 deg C (moderate), and \>38.9 to 40.0 deg C (severe). Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), and severe (prevented daily routine activity). Vomiting was graded mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, and severe: required intravenous hydration. Diarrhea was graded mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h.
| Percentage of participants | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years |
|---|---|---|---|---|---|---|
| Fever: Mild | 0 (0.0 to 13.7) | 4.3 (0.1 to 21.9) | 4.2 (0.1 to 21.1) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 5.0 (0.1 to 24.9) |
| Fever: Moderate | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 5.6 (0.1 to 27.3) | 0 (0.0 to 16.8) |
| Fever: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 5.9 (0.1 to 28.7) | 5.6 (0.1 to 27.3) | 0 (0.0 to 16.8) |
| Fatigue: Mild | 20.0 (6.8 to 40.7) | 21.7 (7.5 to 43.7) | 20.8 (7.1 to 42.2) | 41.2 (18.4 to 67.1) | 16.7 (3.6 to 41.4) | 30.0 (11.9 to 54.3) |
| Fatigue: Moderate | 12.0 (2.5 to 31.2) | 21.7 (7.5 to 43.7) | 8.3 (1.0 to 27.0) | 5.9 (0.1 to 28.7) | 33.3 (13.3 to 59.0) | 5.0 (0.1 to 24.9) |
| Fatigue: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Headache: Mild | 16.0 (4.5 to 36.1) | 26.1 (10.2 to 48.4) | 0 (0.0 to 14.2) | 29.4 (10.3 to 56.0) | 16.7 (3.6 to 41.4) | 0 (0.0 to 16.8) |
| Headache: Moderate | 12.0 (2.5 to 31.2) | 8.7 (1.1 to 28.0) | 4.2 (0.1 to 21.1) | 11.8 (1.5 to 36.4) | 16.7 (3.6 to 41.4) | 0 (0.0 to 16.8) |
| Headache: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Muscle pain: Mild | 16.0 (4.5 to 36.1) | 21.7 (7.5 to 43.7) | 0 (0.0 to 14.2) | 23.5 (6.8 to 49.9) | 33.3 (13.3 to 59.0) | 0 (0.0 to 16.8) |
| Muscle pain: Moderate | 4.0 (0.1 to 20.4) | 17.4 (5.0 to 38.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 5.6 (0.1 to 27.3) | 0 (0.0 to 16.8) |
| Muscle pain: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Joint pain: Mild | 4.0 (0.1 to 20.4) | 4.3 (0.1 to 21.9) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 11.1 (1.4 to 34.7) | 0 (0.0 to 16.8) |
| Joint pain: Moderate | 4.0 (0.1 to 20.4) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Joint pain: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Vomiting: Mild | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 5.9 (0.1 to 28.7) | 5.6 (0.1 to 27.3) | 10.0 (1.2 to 31.7) |
| Vomiting: Moderate | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Vomiting: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Diarrhea: Mild | 4.0 (0.1 to 20.4) | 8.7 (1.1 to 28.0) | 4.2 (0.1 to 21.1) | 0 (0.0 to 19.5) | 5.6 (0.1 to 27.3) | 0 (0.0 to 16.8) |
| Diarrhea: Moderate | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 8.3 (1.0 to 27.0) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
| Diarrhea: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
AE was defined as any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. AEs included serious and all non-serious AE. SAEs were defined as AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was congenital anomaly or birth defect; was suspected transmission via Pfizer product of infectious agent, pathogenic or nonpathogenic or was considered to be an important medical event. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were included.
| Percentage of participants | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 0 (0.0 to 13.7) | 17.4 (5.0 to 38.8) | 12.5 (2.7 to 32.4) | 0 (0.0 to 19.5) | 27.8 (9.7 to 53.5) | 15.0 (3.2 to 37.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as an AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability or incapacity; was a congenital anomaly or birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic or that was considered to be an important medical event.
| Percentage of participants | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study | 0 (0.0 to 13.7) | 4.3 (0.1 to 21.9) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 5.6 (0.1 to 27.3) | 0 (0.0 to 16.8) |
An NDCMC was defined as a disease or medical condition, which was not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study | 0 (0.0 to 13.7) | 0 (0.0 to 14.8) | 0 (0.0 to 14.2) | 0 (0.0 to 19.5) | 0 (0.0 to 18.5) | 0 (0.0 to 16.8) |
Geometric mean titer (GMT) of neutralizing titers (NTs) of respiratory syncytial virus subgroup A and respiratory syncytial virus subgroup B (RSV A and RSV B) before vaccination and 1 month after vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).
| Titer | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| RSV A: Before vaccination | 1168 (706 to 1932) | 2003 (1421 to 2823) | 529 (335 to 835) | 916 (653 to 1285) | 1667 (1035 to 2684) | 561 (309 to 1016) |
| RSV A:1 Month after vaccination | 27862 (21493 to 36119) | 35503 (26876 to 46900) | 26146 (13301 to 51396) | 25341 (15394 to 41715) | 24053 (17440 to 33173) | 11004 (4287 to 28245) |
| RSV B: Before vaccination | 1206 (717 to 2027) | 1905 (1238 to 2930) | 391 (231 to 661) | 965 (668 to 1393) | 1760 (947 to 3272) | 499 (258 to 967) |
| RSV B:1 Month after vaccination | 30251 (21607 to 42355) | 29019 (18786 to 44827) | 16504 (8267 to 32948) | 33351 (23565 to 47202) | 31174 (21756 to 44668) | 10659 (3526 to 32228) |
GMFR of neutralizing titers of RSV A and RSV B from before vaccination to 1 month after vaccination were reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).
| Fold rise | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| RSV A | 21.9 (14.46 to 33.08) | 18.6 (13.03 to 26.55) | 42.8 (23.41 to 78.16) | 27.7 (17.81 to 42.93) | 13.9 (8.75 to 22.03) | 17.7 (9.02 to 34.67) |
| RSV B | 24.4 (15.53 to 38.26) | 16.3 (9.91 to 26.83) | 39.8 (22.96 to 69.08) | 34.6 (21.63 to 55.23) | 17.0 (9.25 to 31.40) | 20.6 (10.00 to 42.50) |
Median frequencies of RSV F antigen-specific CD4+ T cells expressing IFN gamma and IL-4 before vaccination and 1 month after vaccination were reported in this outcome measure. RSV F enzyme-linked immune absorbent spot assay (ELISpot) limit of detection (LOD) values were IFN gamma = 20 spot forming cell (SFC) per million peripheral blood mononuclear cell (PBMCs) and IL-4 = 4 SFC/million PBMCs. Assay results below LOD=0.5\*LOD for analysis. Frequencies were defined as the count of the RSV F antigen-specific CD4+ T cells and median frequencies were defined as the median of the counts.
| SFC/million PBMCs | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to <5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to <5 Years |
|---|---|---|---|---|---|---|
| INF gamma before vaccination | 47 (10 to 241) | 60 (10 to 193) | 10 (10 to 67) | 53 (10 to 277) | 41 (10 to 336) | 10 (10 to 79) |
| INF gamma 1 month after vaccination | 255 (10 to 829) | 293 (10 to 1339) | 61 (10 to 257) | 244 (23 to 1027) | 187 (10 to 780) | 45 (10 to 184) |
| IL-4 before vaccination | 2 (2 to 2) | 2 (2 to 11) | 2 (2 to 2) | 2 (2 to 4) | 2 (2 to 5) | 2 (2 to 4) |
| IL-4 1 month after vaccination | 2 (2 to 16) | 4 (2 to 28) | 2 (2 to 7) | 2 (2 to 24) | 2 (2 to 15) | 2 (2 to 13) |
Collected over Local reactions and systemic events: Within 7 days after vaccination. SAEs: Within 6 months post Vaccination and other AEs: Within 1 month post Vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy RSVpreF 120 Micrograms (mcg) | 0/25 (0%) | 0/25 (0%) | 17/25 (68%) |
| High Risk RSVpreF 120 mcg | 0/23 (0%) | 1/23 (4.3%) | 15/23 (65.2%) |
| 2 to < 5 Years RSVpreF 120 mcg | 0/24 (0%) | 0/24 (0%) | 9/24 (37.5%) |
| Healthy RSVpreF 60 mcg | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| High Risk RSVpreF 60 mcg | 0/18 (0%) | 1/18 (5.6%) | 14/18 (77.8%) |
| 2 to < 5 Years RSVpreF 60 mcg | 0/20 (0%) | 0/20 (0%) | 13/20 (65%) |
| Event | Healthy RSVpreF 120 Micrograms (mcg) | High Risk RSVpreF 120 mcg | 2 to < 5 Years RSVpreF 120 mcg | Healthy RSVpreF 60 mcg | High Risk RSVpreF 60 mcg | 2 to < 5 Years RSVpreF 60 mcg |
|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/25 | 0/23 | 0/24 | 0/17 | 1/18 | 0/20 |
| Food allergyImmune system disorders | 0/25 | 1/23 | 0/24 | 0/17 | 0/18 | 0/20 |
| Event | Healthy RSVpreF 120 Micrograms (mcg) | High Risk RSVpreF 120 mcg | 2 to < 5 Years RSVpreF 120 mcg | Healthy RSVpreF 60 mcg | High Risk RSVpreF 60 mcg | 2 to < 5 Years RSVpreF 60 mcg |
|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 12/25 | 11/23 | 2/24 | 7/17 | 10/18 | 3/20 |
| Fatigue (FATIGUE)General disorders | 8/25 | 10/23 | 7/24 | 8/17 | 9/18 | 7/20 |
| Headache (HEADACHE)Nervous system disorders | 7/25 | 8/23 | 1/24 | 7/17 | 6/18 | 0/20 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 5/25 | 9/23 | 0/24 | 4/17 | 7/18 | 0/20 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 6/25 | 2/23 | 3/24 | 1/17 | 2/18 | 1/20 |
| Swelling (SWELLING)General disorders | 3/25 | 2/23 | 1/24 | 1/17 | 4/18 | 1/20 |
| Injection site painGeneral disorders | 2/25 | 3/23 | 0/24 | 1/17 | 1/18 | 0/20 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 1/25 | 2/23 | 3/24 | 0/17 | 1/18 | 0/20 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 2/25 | 1/23 | 0/24 | 0/17 | 2/18 | 0/20 |
| Pyrexia (FEVER)General disorders | 0/25 | 1/23 | 1/24 | 1/17 | 2/18 | 1/20 |
Safety population included all enrolled participants who received the study intervention.
| Age, Customized(Participants) | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years | Total |
|---|---|---|---|---|---|---|---|
| Children (2-11 years) | 9 | 11 | 24 | 12 | 12 | 20 | 88 |
| Adolescents (12-17 years) | 16 | 12 | 0 | 5 | 6 | 0 | 39 |
| Sex: Female, Male(Participants) | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 11 | 13 | 5 | 7 | 7 | 58 |
| Male | 10 | 12 | 11 | 12 | 11 | 13 | 69 |
| Ethnicity (NIH/OMB)(Participants) | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 1 | 3 | 4 | 5 | 18 |
| Not Hispanic or Latino | 20 | 23 | 22 | 14 | 13 | 15 | 107 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 120 mcg: 2 to < 5 Years | RSVpreF 60 mcg: 5 to <18 Years [Healthy Participants] | RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants] | RSVpreF 60 mcg: 2 to < 5 Years | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 6 | 3 | 2 | 6 | 4 | 28 |
| White | 16 | 17 | 17 | 13 | 9 | 15 | 87 |
| More than one race | 0 | 0 | 3 | 2 | 3 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2023 to primary completion in Feb 2024, 8 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 8 months is above that.
Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →